Distinguished in Angiosarcoma

Dr. Hari A. Deshpande

Interventional Cardiology | Oncology | Hematology
Yale University
20 York St, 
New Haven, CT 
Offers Telehealth
Distinguished in Angiosarcoma
Yale University
20 York St, 
New Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Hari Deshpande is an Interventional Cardiologist and an Oncologist in New Haven, Connecticut. Dr. Deshpande is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Adult Soft Tissue Sarcoma, Desmoid Tumor, Liposarcoma, Alveolar Soft Part Sarcoma, and Gastrostomy.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 13 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 1 clinical trial in the study of Angiosarcoma.

Specialties
Interventional Cardiology
Oncology
Hematology
Licenses
Internal Medicine in CT
Hospital Affiliations
Westerly Hospital
Yale-New Haven Hospital
Bridgeport Hospital
Lawrence & Memorial Hospital
Greenwich Hospital Association -
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

YALE UNIVERSITY
20 York St, New Haven, CT 06510

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
A Multicenter Phase II Trial of Paclitaxel With and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects With Angiosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib-S-Malate, Nivolumab, Paclitaxel
Study Phase: Phase 2
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: October 08, 2025
Intervention Type: Procedure, Biological, Drug
Study Drugs: Atezolizumab, Bevacizumab
Study Phase: Phase 2
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
A Phase 2 Study of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Procedure, Drug
Study Phase: Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
A Phase II Study of the Peroxisome Proliferator-Activated Receptor Gamma Agonist, Efatutazone in Patients With Previously Treated, Unresectable Myxoid Liposarcoma
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drug: Efatutazone
Study Phase: Phase 2
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
A Phase 2 Study of Efatutazone, an Oral PPAR Agonist, In Combination With Paclitaxel in Patients With Advanced Anaplastic Thyroid Cancer
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Efatutazone, Paclitaxel
Study Phase: Phase 2
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
A Non-Randomized, Open-Label, Phase 2 Study of Trametinib in Patients With Unresectable or Metastatic Epithelioid Hemangioendothelioma
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Other, Drug
Study Drug: Trametinib
Study Phase: Phase 2
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) VS. Pazopanib in Patients With Locally Advanced/Unresectable and/or Metastatic Sarcoma
Enrollment Status: Terminated
Publish Date: August 23, 2022
Intervention Type: Drug
Study Drugs: Pazopanib, Pazopanib Hydrochloride, Sapanisertib
Study Phase: Phase 1/Phase 2
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
A Window Study to Assess the Activity of Demethylation Therapy in Patients With HPV-Positive Compared With HPV-Negative Head and Neck Squamous Cell Carcinoma, With Response Assessment and Biomarker Expansion Cohort in HPV-Positive Oropharynx Cancer
Enrollment Status: Completed
Publish Date: February 15, 2022
Intervention Type: Drug
Study Drug: 5-Azacitadine
Study Phase: Phase 1
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
A Phase 1b Trial to Assess the Modulation of Biological Markers in Patients With Potentially Resectable Soft Tissue Sarcoma Treated With Olaratumab Monotherapy Followed by Olaratumab Plus Doxorubicin Combination Therapy
Enrollment Status: Completed
Publish Date: August 12, 2019
Intervention Type: Drug, Radiation
Study Phase: Phase 1
View 12 Less Clinical Trials

32 Total Publications

Twenty-five years without progress: The enduring challenge of soft tissue sarcomas.
Twenty-five years without progress: The enduring challenge of soft tissue sarcomas.
Journal: Cancer
Published: May 21, 2025
Similar Doctors
Distinguished in Angiosarcoma
Dr. Julie M. Gold
Oncology | Hematology
Distinguished in Angiosarcoma
Dr. Julie M. Gold
Oncology | Hematology

Optum Medical Care PC

90 S Bedford Rd, 
Mount Kisco, NY 
 (41.4 miles away)
914-241-1050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Julie Gold is an Oncologist and a Hematologist in Mount Kisco, New York. Dr. Gold is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Inflammatory Breast Cancer, Angiosarcoma, Paget Disease of the Breast, and HER-2 Positive Breast Cancer.

Distinguished in Angiosarcoma
Dr. Andrea L. Dickey
Oncology | Hematology Oncology
Distinguished in Angiosarcoma
Dr. Andrea L. Dickey
Oncology | Hematology Oncology

Yale University

111 Goose Ln, 
Guilford, CT 
 (14.1 miles away)
203-747-7300
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Andrea Dickey is an Oncologist and a Hematologist Oncology provider in Guilford, Connecticut. Dr. Dickey is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer.

Distinguished in Angiosarcoma
Dr. Dickerman Hollister
Oncology | Hematology
Distinguished in Angiosarcoma
Dr. Dickerman Hollister
Oncology | Hematology
77 Lafayette Pl, 
Greenwich, CT 
 (40.6 miles away)
203-863-3737
Languages Spoken:
English
See accepted insurances

Dickerman Hollister is an Oncologist and a Hematologist in Greenwich, Connecticut. Dr. Hollister is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Angiosarcoma, Inflammatory Breast Cancer, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Paget Disease of the Breast.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Deshpande's expertise for a condition
ConditionClose
    View All 26 Distinguished Conditions
    View All 23 Advanced Conditions
    View All 54 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile